GlassScriptPhysician profile
Ariel Karwat
NPI 1427648179
$1,652.56
in general payments reported to CMS, 2019-2025
27 companies · $705 in 2025
The $705 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2023: $143 · 2024: $184 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.88 |
| Education | $119.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $274.44 | 2021-2025 | |
| Recordati_rare_diseases_inc. | $163.15 | 2025 | Sylvant |
| Lilly USA, LLC | $150.67 | 2021-2025 | |
| Incyte Corporation | $120.19 | 2021 | |
| Stemline Therapeutics INC. | $102.26 | 2021-2025 | Orserdu |
| E.R. Squibb & Sons, L.L.C. | $89.98 | 2021 | |
| Janssen Biotech, INC. | $86.44 | 2023-2025 | Darzalex, Talvey, Balversa |
| Myriad Genetic Laboratories, INC. | $60.62 | 2023 | Precisetumor |
| Amgen INC. | $58.90 | 2021 | |
| Merck Sharp & Dohme LLC | $53.07 | 2025 | Lynparza, Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $50.15 | 2023 | Epkinly, Imbruvica |
| Seagen INC. | $48.91 | 2021 | |
| Daiichi Sankyo INC. | $47.58 | 2024-2025 | Vanflyta, Enhertu |
| Genzyme Corporation | $44.46 | 2021 | |
| Deciphera Pharmaceuticals INC. | $40.63 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $38.19 | 2021-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $31.41 | 2021-2025 | Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $30.33 | 2024-2025 | Fruzaqla |
| Gilead Sciences, INC. | $28.63 | 2025 | Trodelvy |
| Ipsen Biopharmaceuticals, INC | $18.22 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.71 | 2025 | Ultomiris |
| Amag Pharmaceuticals, INC. | $17.61 | 2021 | |
| Taiho Oncology, INC. | $17.38 | 2021 | |
| Pharmaessentia USA Corporation | $17.31 | 2025 | Besremi |
| Myovant Sciences INC. | $15.64 | 2021 | |
| Emd Serono, INC. | $14.57 | 2021 | |
| Epizyme, INC. | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Karwat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.